転移性非小細胞肺がん市場 - 市場の洞察、疫学、市場予測：2032年

2022年の主要7ヶ国における転移性非小細胞肺がん（NSCLC）の総発生症例数は約52万7,000例であり、これらの症例数は2032年までに増加すると推定されます。EU4ヶ国の中で、2019年のNSCLC症例数が最も多かったのはドイツであり、一方、2019年の症例数が最も少なかったのはスペインでした。NSCLCは患者の50％近くで進行期と診断されます。スクリーニングと発見の増加により、ステージIのNSCLCの発生率は同時に上昇し、ステージIVのNSCLCは減少しています。

非小細胞肺がんは最も一般的な肺がんで、肺がん診断全体の81％を占めます。非小細胞肺がんは早期診断が最良の予後をもたらします。しかし、非小細胞肺がんをはじめとする肺がんは、一般的な病気や長期間の喫煙の影響と間違われる症状が多いため、診断が難しいことがあります。このため、非小細胞肺がんと診断された人の80％はすでに進行しており、治療が難しくなっています。肺がんが疑われる場合、医師は肺やその周辺の異常を特定するための画像検査（CT、PET、MRI検査）を勧めます。また、粘液のサンプルを顕微鏡で検査することもあります。

これらの初期検査でがんが確認された場合は、肺生検を実施することもあります。気管支鏡検査も勧められることがあり、これにより医師は組織を可視化して切除することができます。肺がんが確認された場合、肺組織について遺伝子検査を行い、治療に役立つがんの詳細を特定することができます。

当レポートでは、主要7ヶ国における転移性非小細胞肺がん市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 主なハイライト

第4章 エグゼクティブサマリー

第5章 転移性NSCLC疫学の概要の概要

第6章 疫学の調査手法

第7章 疾患の背景と概要

• イントロダクション

第8章 NSCLCの診断

• NSCLCの段階
• 病期判定システム

第9章 疫学と患者数

• 主な調査結果
• 仮定と根拠：主要7ヶ国
• 主要7ヶ国におけるNSCLCの総発生件数
• 米国の疫学
• EU4ヶ国と英国の疫学
• 日本の疫学

第10章 付録

• 参考文献
• レポート調査手法

第11章 DelveInsightのサービス内容

第12章 免責事項

第13章 DelveInsightについて

List of Tables

• Table 1: Summary of NSCLC Epidemiology (2019-2032)
• Table 2: TNM Staging of NSCLC
• Table 3: Total Incident Cases of NSCLC in the 7MM (2019-2032)
• Table 4: Total Incident Cases of NSCLC in the United States (2019-2032)
• Table 5: Gender-specific Cases of NSCLC in the United States (2019-2032)
• Table 6: Age-specific Cases of NSCLC in the United States (2019-2032)
• Table 7: Total Incident Cases of NSCLC by Histology in the United States (2019-2032)
• Table 8: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2019-2032)
• Table 9: Total Incident Cases of Advanced/Metastatic NSCLC in the United States (2019-2032)
• Table 10: Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States (2019-2032)
• Table 11: Line-wise Treated Cases of Metastatic NSCLC in the United States (2019-2032)
• Table 12: Total Incident Cases of NSCLC in EU4 and the UK (2019-2032)
• Table 13: Gender-specific Cases of NSCLC in EU4 and the UK (2019-2032)
• Table 14: Age-specific Cases of NSCLC in EU4 and the UK (2019-2032)
• Table 15: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2019-2032)
• Table 16: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2019-2032)
• Table 17: Total Incident Cases of Advanced/Metastatic NSCLC in the EU4 and the UK (2019-2032)
• Table 18: Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK (2019-2032)
• Table 19: Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK (2019-2032)
• Table 20: Total Incident Cases of NSCLC in Japan (2019-2032)
• Table 21: Gender-specific Cases of NSCLC in Japan (2019-2032)
• Table 22: Age-specific Cases of NSCLC in Japan (2019-2032)
• Table 23: Total Incident Cases of NSCLC by Histology in Japan (2019-2032)
• Table 24: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2019-2032)
• Table 25: Total Incident Cases of Advanced/Metastatic NSCLC in Japan (2019-2032)
• Table 26: Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan (2019-2032)
• Table 27: Line-wise Treated Cases of Metastatic NSCLC in Japan (2019-2032)

List of Figures

• Figure 1: Major Types of NSCLC
• Figure 2: Signs and Symptoms of NSCLC
• Figure 3: Risk Factors of NSCLC
• Figure 4: Stage IIIB Lung Cancer
• Figure 5: Stage IIIC Lung Cancer
• Figure 6: Stage IVA Lung Cancer
• Figure 7: Stage IVB Lung Cancer
• Figure 8: Tumor Biomarker Testing Rate
• Figure 9: Total Incident Cases of NSCLC in the 7MM (2019-2032)
• Figure 10: Total Incident Cases of NSCLC in the United States (2019-2032)
• Figure 11: Gender-specific Cases of NSCLC in the United States (2019-2032)
• Figure 12: Age-specific Cases of NSCLC in the United States (2019-2032)
• Figure 13: Total Incident Cases of NSCLC by Histology in the United States (2019-2032)
• Figure 14: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2019-2032)
• Figure 15: Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States (2019-2032)
• Figure 16: Line-wise Treated Cases of Metastatic NSCLC in the United States (2019-2032)
• Figure 17: Total Incident Cases of NSCLC in EU4 and the UK (2019-2032)
• Figure 18: Gender-specific Cases of NSCLC in EU4 and the UK (2019-2032)
• Figure 19: Age-specific Cases of NSCLC in EU4 and the UK (2019-2032)
• Figure 20: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2019-2032)
• Figure 21: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2019-2032)
• Figure 22: Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK (2019-2032)
• Figure 23: Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK (2019-2032)
• Figure 24: Total Incident Cases of NSCLC in Japan (2019-2032)
• Figure 25: Gender-specific Cases of NSCLC in Japan (2019-2032)
• Figure 26: Age-specific Cases of NSCLC in Japan (2019-2032)
• Figure 27: Total Incident Cases of NSCLC by Histology in Japan (2019-2032)
• Figure 28: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2019-2032)
• Figure 29: Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan (2019-2032)
• Figure 30: Line-wise Treated Cases of Metastatic NSCLC in Japan (2019-2032)

Key Highlights:

• As per DelveInsight's analysis, the total incident cases of NSCLC in the 7MM were approximately 527,000 cases in 2022; these cases are estimated to increase by 2032.
• Among EU4 countries, Germany accounted for the highest number of NSCLC cases in 2019, whereas Spain accounted for the lowest cases in 2019.
• NSCLC is diagnosed at an advanced stage in nearly 50% of patients. Increased screening and detection have resulted in a concomitant rise in the incidence of Stage I NSCLC and a decline in Stage IV NSCLC.
• Various types of mutations are commonly observed in NSCLC. There is mounting evidence that substantial molecular and clinical heterogeneity exists within oncogenic driver-defined subgroups of NSCLC. The most frequent biomarkers are EGFR in Japan and KRAS in the US and Europe.
• EGFR exon 19 deletions and Exon 21 L858R substitution (sensitizing mutations) account for approximately 80% of EGFR mutations in NSCLC.
• The total incident cases of EGFR Non-small Cell Lung Cancer in the US was ~30,000 in 2022.
• The most frequent KRAS variant observed in NSCLC is G12C. In the United States, KRASG12C is present in ~37% of NSCLC cases.
• In 2022, the total incident cases of NTRK metastatic Non-small Cell Lung Cancer in the 7MM was around 1,100.

DelveInsight's "Metastatic Non-small Cell Lung Cancer - Epidemiology - 2032" report delivers an in-depth understanding of metastatic non-small cell lung cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Metastatic Non-small Cell Lung Cancer Disease Understanding

Metastatic Non-small Cell Lung Cancer Overview and Diagnosis

Non-small Cell Lung Cancer is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. Early diagnosis offers the best prognosis for Non-Small Cell Lung Cancer. However, Non-Small Cell Lung Cancer and other lung cancers can be difficult to diagnose because these cancers often have symptoms mistaken for common illnesses or the effects of long-term smoking. Because of this, 80% of people diagnosed with Non-Small Cell Lung Cancer have already progressed to advanced stages, making it more difficult to treat. If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around the lungs. The physician may also examine a sample of mucus under the microscope.

If these initial tests identify cancer, a lung biopsy can be conducted. A bronchoscopy can also be recommended, allowing the physician to visualize and remove tissue. If lung cancer is confirmed, genetic testing can be done on the lung tissue to identify details about the cancer that can help inform treatment.

Further details related to country-based variations in diagnosis are provided in the report…

Metastatic Non-small Cell Lung Cancer Epidemiology

The Metastatic Non-small Cell Lung Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Non-small Cell Lung Cancer, total incident cases of Non-small Cell Lung Cancer by histology, total cases of Non-small Cell Lung Cancer by stages, total incident cases of Non-small Cell Lung Cancer by genetic mutation/biomarkers, total treated cases of Non-small Cell Lung Cancer by line of therapies in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In the US, in 2022, there were approximately 200,000 new cases of lung cancer (~113,000 in men and ~88,000 in women). About 10-15% of all lung cancers are SCLC, and about 80-85% are Non-Small Cell Lung Cancer.
• The three main histological subtypes of Non-Small Cell Lung Cancer are Adenocarcinoma, Squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the United States, approximately 57% of all lung cancers are adenocarcinomas. About 25-30% of all lung cancers are Squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 2% of all lung cancers.
• Among the age-specific contribution, age =65 years are affected more by NSCLC than age <65 years. In 2019, there were 132,764 cases of NSCLC in age =65 years in the United States.
• In the US, in 2022, there were approximately 110,000 metastatic cases of NSCLC (De novo advanced/metastatic patients and recurrent patients from early stages).
• The two main subtypes of KRAS Non-Small Cell Lung Cancer are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~22,000 cases comprised of KRAS G12C, and ~38,000 cases comprised of KRAS non-G12C in 2022.

Scope of the Report:

• The report covers a segment of executive summary, and a descriptive overview of metastatic non-small cell lung cancer, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of the metastatic non-small cell lung cancer epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Metastatic Non-Small Cell Lung Cancer Report Insights

• Patient Population
• Patient population by stage and age
• Country-wise Epidemiology Distribution

Metastatic Non-Small Cell Lung Cancer Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Metastatic Non-small Cell Lung Cancer Epidemiology Segmentation

Metastatic Non-Small Cell Lung Cancer Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs:

• What are the disease risks and burdens of metastatic non-small cell lung cancer? What will be the growth opportunities across the 7MM concerning the patient population with metastatic non-small cell lung cancer?
• What is the historical and forecasted non-small cell lung cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which age group is the largest contributor in patients affected with metastatic non-small cell lung cancer?
• Which biomarker has the highest patient share in metastatic non-small cell lung cancer?

Reasons to buy:

• Insights on patient disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Table of Contents

1. Key Insights

2. Report Introduction

3. Key Highlights

4. Executive Summary

5. Metastatic NSCLC Epidemiology Overview at a Glance

• 5.1. Patient Share (%) Distribution by Immune/Molecular Biomarker in 2019
• 5.2. Patient Share (%) Distribution by Immune/Molecular Biomarker in 2032

6. Epidemiology Methodology

7. Disease Background and Overview

• 7.1. Introduction
  • 7.1.1. Cellular Classification of NSCLC
  • 7.1.2. Signs and Symptoms of NSCLC
  • 7.1.3. Risk Factors of Lung Cancer
  • 7.1.4. Causes of NSCLC
  • 7.1.5. Disease Biology: NSCLC
    • 7.1.5.1. Genomic Alterations
    • 7.1.5.2. Tumor Microenvironment

8. Diagnosis of NSCLC

• 8.1. Stages of NSCLC
• 8.2. Staging System

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
• 9.3. Total Incident Cases of NSCLC in the 7MM
• 9.4. United States Epidemiology
  • 9.4.1. Total Incident Cases of NSCLC in the United States
  • 9.4.2. Gender-specific Cases of NSCLC in the United States
  • 9.4.3. Age-specific Cases of NSCLC in the United States
  • 9.4.4. Total Incident Cases of NSCLC by Histology in the United States
  • 9.4.5. Total Incident Cases of NSCLC by Stage in the United States
  • 9.4.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States
  • 9.4.7. Line-wise Treated Cases of Metastatic NSCLC in the United States
• 9.5. EU4 and the UK Epidemiology
  • 9.5.1. Total Incident Cases of NSCLC in EU4 and the UK
  • 9.5.2. Gender-specific Cases of NSCLC in EU4 and the UK
  • 9.5.3. Age-specific Cases of NSCLC in EU4 and the UK
  • 9.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK
  • 9.5.5. Total Incident Cases of NSCLC by Stage in EU4 and the UK
  • 9.5.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK
  • 9.5.7. Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK
• 9.6. Japan Epidemiology
  • 9.6.1. Total Incident Cases of NSCLC in Japan
  • 9.6.2. Gender-specific Cases of NSCLC in Japan
  • 9.6.3. Age-specific Cases of NSCLC in Japan
  • 9.6.4. Total Incident Cases of NSCLC by Histology in Japan
  • 9.6.5. Total Incident Cases of NSCLC by Stage in Japan
  • 9.6.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan
  • 9.6.7. Line-wise Treated Cases of Metastatic NSCLC in Japan

10. Appendix

• 10.1. Bibliography
• 10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight